Advances in Multiple Sclerosis Neurotherapeutics, Neuroprotection, and Risk Mitigation Strategies
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Advances in Multiple Sclerosis Neurotherapeutics, Neuroprotection, and Risk Mitigation Strategies
Authors
Keywords
-
Journal
NEUROLOGIC CLINICS
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-09-09
DOI
10.1016/j.ncl.2023.08.002
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation
- (2023) Chao Zhu et al. JAMA Neurology
- Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial
- (2023) John R Corboy et al. LANCET NEUROLOGY
- Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis
- (2022) Brandi L. Vollmer et al. Frontiers in Neurology
- Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study
- (2022) Sibyl Wray et al. ADVANCES IN THERAPY
- Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
- (2022) John F Foley et al. LANCET NEUROLOGY
- Phase 1 Evaluation of Elezanumab ( anti‐RGMa mAb ) in Healthy and MS Participants
- (2022) Hari V. Kalluri et al. ANNALS OF NEUROLOGY
- Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
- (2022) Lawrence Steinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Updates and advances in multiple sclerosis neurotherapeutics
- (2022) Moein Amin et al. Neurodegenerative Disease Management
- The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination
- (2022) David Baker et al. Multiple Sclerosis and Related Disorders
- Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis
- (2021) Amber Salter et al. JAMA Neurology
- Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
- (2021) Arpan Patel et al. JAMA Neurology
- Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions
- (2021) Marisa P McGinley et al. LANCET
- Ofatumumab versus Teriflunomide in Multiple Sclerosis
- (2020) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Serious safety events in rituximab‐treated multiple sclerosis and related disorders
- (2020) Brandi L. Vollmer et al. Annals of Clinical and Translational Neurology
- Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
- (2020) Brandi L. Vollmer et al. Annals of Clinical and Translational Neurology
- Intracerebral haemorrhage during alemtuzumab administration
- (2019) Christina J Azevedo et al. LANCET NEUROLOGY
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
- (2019) Gustavo Luna et al. JAMA Neurology
- Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up
- (2019) Brandi Vollmer et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Current advancements in promoting remyelination in multiple sclerosis
- (2018) David Kremer et al. Multiple Sclerosis Journal
- Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis
- (2018) Maria R Ciardi et al. Open Forum Infectious Diseases
- Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial
- (2017) Ari J Green et al. LANCET
- Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
- (2017) Gavin Giovannoni et al. Multiple Sclerosis Journal
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
- (2017) Gavin Giovannoni et al. Multiple Sclerosis Journal
- MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
- (2016) Ayman Tourbah et al. Multiple Sclerosis Journal
- Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis
- (2016) Frédéric Sedel et al. NEUROPHARMACOLOGY
- MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
- (2016) Ayman Tourbah et al. Multiple Sclerosis Journal
- Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
- (2015) Tobias Ruck et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial
- (2014) Jeremy Chataway et al. LANCET
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis
- (2014) Feng Mei et al. NATURE MEDICINE
- Risk stratification and mitigation in multiple sclerosis
- (2014) Daniel Ontaneda et al. Multiple Sclerosis and Related Disorders
- Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation
- (2013) David Kremer et al. ANNALS OF NEUROLOGY
- Blocking LINGO-1 as a Therapy to Promote CNS Repair: From Concept to the Clinic
- (2013) Sha Mi et al. CNS DRUGS
- Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude
- (2013) R. Dobson et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Alemtuzumab more effective than interferon -1a at 5-year follow-up of CAMMS223 Clinical Trial
- (2012) A. J. Coles et al. NEUROLOGY
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Beta-interferon for multiple sclerosis
- (2011) Richard A. Rudick et al. EXPERIMENTAL CELL RESEARCH
- Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial
- (2011) Per Soelberg Sorensen et al. LANCET NEUROLOGY
- Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
- (2011) Stephen Sawcer et al. NATURE
- Evidence-based guideline update: Plasmapheresis in neurologic disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
- (2011) I. Cortese et al. NEUROLOGY
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
- (2010) Gavin Giovannoni et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Human Endogenous Retrovirus Link between Genes and Environment in Multiple Sclerosis and in Multifactorial Diseases Associating Neuroinflammation
- (2009) Hervé Perron et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study
- (2009) D. Cadavid et al. NEUROLOGY
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
- (2008) Daniel D Mikol et al. LANCET NEUROLOGY
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now